Frost predicts tripling of non-mammo breast imaging in U.S.

The advent of adjunctive imaging modalities such as MRI, nuclear breast imaging, and automated biopsy are supplementing mammography’s role as the gold standard in the early detection and diagnosis of breast cancer, according to a report published by market research firm Frost & Sullivan of San Jose, CA.

Frost said that U.S. revenues in the industry totaled $22 million in 2002 and are projected to reach $64.7 million by 2010.

The firm noted that significant reimbursement issues for nuclear imaging, breast MRI, and emerging technologies such as laser tomography and clinical thermography are limiting market penetration. The need to create a compelling case to be reimbursed is keeping many physicians from undertaking these procedures at all, Frost said.

According to Frost & Sullivan research analyst Antonio Garcia, lobbying for the establishment of secured reimbursement streams for adjunctive technologies must be viewed as an important part of the overall campaign to create growth opportunities in the market.

The report, North American Adjunctive Breast Imaging and Automated Biopsy Equipment Markets, said that manufacturers also have to contend with the increasing closure of breast imaging facilities due to financial difficulties as well as the widespread perception among clinicians that traditional mammography, perhaps combined with ultrasound for radiodense breasts, is sufficient for the early detection of cancer.

By staff writers
December 9, 2003

Related Reading

Frost sees growth in European equipment-services market, August 7, 2003

Image-guided/robot-assisted surgery markets to grow, June 18, 2003

Shift to full-field digital units will spur mammography market, April 30, 2003

Frost report pegs MRI market growth at 21% in 2002, April 22, 2003

PET/CT growth sparks gains in U.S. PET market, April 15, 2003

Copyright © 2003

Page 1 of 570
Next Page